—Bachelor's degree in Chemistry from Peking University, Master's degree in Bioanalytical Chemistry from Rutgers University, and MBA from New York University's Stern School of Business.

—Held key positions in major multinational pharmaceutical companies such as GlaxoSmithKline, Cardinal Health, and Mylan, with 30 years of experience in the bio-pharmaceutical industry across China, the United States, and internationally.

Master of Economics, Fudan University

Non-practicing Member of the Chinese Institute of Certified Public Accountants (CICPA); Holder of the Qualified Sponsor Representative Qualification of China; Possessor of Hong Kong Securities and Futures Commission (SFC) Type 1, 4 and 6 Licenses; Certified Internal Auditor (CIA); Holder of the China Securities Practitioner Qualification

Previously served at PricewaterhouseCoopers (PwC), Deloitte Touche Tohmatsu Limited (Deloitte) and GlaxoSmithKline (China), engaging in audit assurance, risk consulting and other related work; Worked in domestic and overseas investment banking businesses at 3 securities companies including China International Capital Corporation Limited (CICC); Chief Financial Officer (CFO) at Wuhan Weike Medical Technology Co., Ltd. and Hunan Hengchang Pharmaceutical Group Co., Ltd.

With nearly 18 years of experience in capital operations and financial management, including more than 10 years of investment banking experience, and has a profound understanding of domestic and overseas capital operations

— Master in Pharmacognosy,Peking University Health Science Center，MBA in Harvard Business School.

— Worked as deputy director of product design center in Taiji Group in Beijing,

— Since 2016 entry 3D Medicines，has been serverd as the head of regulatory affairs of the Group and the vice president (副總經理) of 3D Medicines

—Member of the Hong Kong Investor Relations Association and a member of the fourth (2022 2024) Professional Committee on China Pharmaceutical Innovation and Research Development Association (PhIRDA)

— Bachelor in Finance, Suzhou University

— Previous experience in WuXi AppTec, JOINN Laboratories and BL Pharma, over 15 years' operation management experience

— Master in Clinical Medicine in Sichuan University, MBA in Hong Kong Asia Business College

— Worked for BeiGene,  Ronggang Biotechnology Pharma and Baitai Biopharmaceutical, 13 years of experience in the pharmaceutical industry。

— Master in Medicinal Chemistry, Peking University; Ph.D. in Bioorganic Chemistry, University College Dublin, Ireland; Post-doc, National University of Ireland-Galway, Ireland

— Comprehensive experience in drug R&D, manufacturing, quality research and the construction of pharmaceutical plants

— Bachelor of Pharmacy, Xi'an Jiaotong University, Master and Ph.D. in Cell Biology, Fourth Military Medical University

— Worked for the Fourth Military Medical University, Jiangsu Pacific Minox, CANbridge, Henlius and other universities and pharmaceutical enterprises, and his working experience covers different stages of drug R&D and production. Published a number of SCI papers, obtained a number of patents, and undertaken or participated in a number of national key scientific research projects

—Master of Medicine degree in Seven-Years-Program of Clinical Medicine, Medical college of Xi’an Jiao Tong University Doctor of Medicine degree from Peking Union Medical College

—She worked at Institute of Hematology &Blood Diseases Hospital, Peking Union Medical College;she served as the MSM leader for oncology at Bristol-Myers Squibb China（百时美施贵宝有限公司）、the disease area head at Roche Shanghai、the medical director at Qilu Pharmaceutical co.,ltd.、medical director at Xuanzhu Biopharm.

—She has 15 years of experience in the pharmaceutical industry and 3 years of experience as a clinical hematology specialist.

—Doctorate degree in internal medicine (Hematology) from the Shanghai JiaoTong University School of Medicine (上海交通大学医学院), Postdoctoral researcher in Kansas University Medical School

—He was a Researcher associate at The Ohio State University Comprehensive Cancer Center;and he worked was the director of cancer vaccine in Stemirna Therapeutics Co., Ltd. （斯微生物科技股份有限公司）.

—Fangqiang Tang(唐方强)， Director of CMC research and development of small molecules Master's degree in the Pharmaceutical Chemistry in Shenyang Pharmaceutical University （沈阳药科大学。He is certified as a PMP by the Project Management Institute and as a Licensed Pharmacist by the Certification Center for Licensed Pharmacist of NMPA.

—He worked at Wuxi AppTec, a company listed on the Shanghai Stock Exchange (stock code: 603259.SH) and the Hongkong Stock Exchange (stock code: 2359.HK).

—Then，he served as the R&D Senior Manager at Shanghai Knowshine Inc. Mr. Tang has 18 years of working experiences in the pharmaceutical industry, with substantial expertise in CMC R&D for both generic and innovative drugs.